Some analysts have picked “winners and losers” from the 2018 J.P. Morgan Healthcare Conference. CNBC’s Jim Cramer made his picks related to stock performance.

Amgen and Novartis announced that they expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in Alzheimer’s.

Eli Lilly’s drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial.

After posting mixed results for its pimavanserin trial in December 2016, Acadia Pharmaceuticals is broadening its research focus from Alzheimer’s disease psychosis to the treatment of hallucinations and delusions associated with dementia-related psychosis.

Shares of Arbutus Biopharma Corporation shot up after biotech investor Vivek Ramaswamy’s Roivant Sciences upped its stake in the company by $116.4 million to advance that company’s hepatitis B program.

Researchers have discovered a protein that could help diagnose a degenerative brain disease commonly found in athletes, veterans of military service and others who have experienced brain trauma.

Drug developer Axovant Sciences Ltd. said it would stop testing the company’s lead drug in Alzheimer’s after it failed to meet the main goals of a late-stage trial.

Science needs champions. That is the belief of Johnson & Johnson’s Seema Kumar, vice president of Innovation, Global Health and Science Policy Communication. And that is a belief being harnessed by a new J&J initiative that celebrates the legacy of Dr. Paul Janssen, one of the most prolific scientific innovators of the past century.

Eli Lilly and Company announced the company plans to cut 3,500 jobs. The majority of the job cuts will be in the U.S., and include voluntary early retirement programs.

Pharma and biotech companies have been scrambling for years to develop therapies to treat patients with Alzheimer’s disease. As those companies look to develop treatments, MyndYou has created an artificial intelligence diagnostics tool to track the subtle changes in speech patterns of Alzheimer’s patients.